Reports indicate that the biopharma sector is expected to see increased merger and acquisition activity in 2026. The outlook is described as dynamic, with the biopharma ecosystem reportedly back to full health, fueled by M&A. Multiple firms, including Goldman Sachs, J.P. Morgan, and others, are releasing reports on the trend, suggesting a surge in dealmaking and strategic partnerships in the life sciences industry.